BRISTOL MYERS SQUIBB

FDA approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for adult solid tumors, marking the first subcutaneously administered PD-1 inhibitor. It's indicated for various cancers but not with IV ipilimumab. Approval based on CheckMate-67T trial showing noninferiority and comparable efficacy to IV nivolumab.

Drugmakers plan to raise U.S. prices on over 250 branded medications in 2025, with most increases below 10%. Pfizer, Bristol Myers Squibb, and Sanofi are among those adjusting prices, citing inflation and investment needs. The U.S. continues to pay the highest for prescription drugs globally.

Starting January 1, over 250 US medications, including Pfizer's Paxlovid and Sanofi's vaccines, will see price increases, mostly under 10%. Pfizer, Bristol Myers, and Sanofi lead with hikes between 3% to 9%. Leadiant Pharmaceuticals tops with 15-20% increases on specific treatments.

Cell therapy, especially CAR-T, is advancing in autoimmune disease treatment, showing promise in early trials for diseases like lupus. Despite no phase 3 approvals yet, its potential for curative effects excites the field. Companies like Kyverna, Cabaletta, and Cartesian lead in phase 2 trials, with mixed results. Long-term data and safety are crucial for broader application.

FDA approves injectable Opdivo for cancer. Anthem Biosciences proposes $397M IPO. France reports bird flu in poultry. China defends COVID-19 data sharing. Hain Celestial sued over arsenic in baby food. Novartis advances gene therapy for muscle disorder. UK approves Merck's lung disease drug. Pfizer ends hemophilia A therapy with Sangamo. U.S. drug prices to rise for over 250 medications.

2024 saw significant FDA approvals, including semaglutide for cardiovascular risk reduction, dupilumab for pediatric eosinophilic esophagitis, ensifentrine for COPD, resmetirom for NASH, donanemab for Alzheimer's, tirzepatide for sleep apnea, xanomeline/trospium for schizophrenia, acoramidis for ATTR-CM, Pfizer's RSV vaccine, and berdazimer gel for molluscum contagiosum.

The AI in clinical trials market is projected to grow from US$3.003 billion in 2021 to US$37.093 billion by 2028, driven by the need for faster drug development, especially for rare and genetic diseases, and the labor-intensive nature of clinical trials. North America leads in market potential, with significant investments in AI technologies by pharmaceutical companies to enhance trial efficiency and drug discovery. Challenges include data bias and the unavailability of comprehensive datasets for new diseases.

Drugmakers plan to raise US prices on over 250 branded medications in 2025, with most increases below 10%. Pfizer leads with over 60 drugs, including a 3% hike on Paxlovid. Despite reductions on some drugs, the US continues to pay the highest for prescription medicines globally.

U.S. medications, including COVID-19 treatment Paxlovid and cancer therapies, will see a price hike starting January 1, 2025, with increases below 10% and an average of 4.5%. Drugmakers face constraints on price increases, leading to higher launch prices for new medicines.